CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

Update: 2024-07-31

Description

Novel Psychedelics drug developer Cybin's CEO Doug Drydale joins WTR's Tim Gerdman and Robert Sassoon to talk about the company's fast-track development into a late-stage clinical development company, and what differentiates Cybin from other drug developers in the psychedelics space. Drysdale discusses Cybin's plans and priorities for its development pipeline going forward and talks about the company's extensive IP real estate. He also shares his perspectives on the regulatory uncertainty currently surrounding Lykos's MDMA-AT and how Cybin is dealing with it to its benefit

Comments

Top Podcasts

The Best New Comedy Podcast Right Now – June 2024 The Best News Podcast Right Now – June 2024 The Best New Business Podcast Right Now – June 2024 The Best New Sports Podcast Right Now – June 2024 The Best New True Crime Podcast Right Now – June 2024 The Best New Joe Rogan Experience Podcast Right Now – June 20 The Best New Dan Bongino Show Podcast Right Now – June 20 The Best New Mark Levin Podcast – June 2024

In Channel

Gorilla Technology Group (GRRR): CEO and CFO Discuss What Is Driving Triple Digit Growth

2024-11-0624:53

Hydrofarm Holdings Group, Inc. Initiation of Coverage Review: The Benefits of Ancillary Companies

2024-11-0412:27

Arq Inc. Initiation of Coverage Review: Leader in Activated Carbon

2024-10-3008:05

Ainos Inc. Director of Corporate Development Jack Lu on Veldona Drug Development

2024-10-2322:14

The evolution of iPower business model, from online selling to becoming a key service provider for other consumer goods companies

2024-10-1625:32

LSB Industries (LXU) CEO Mark Behrman on How CCS and Low Carbon Ammonia Drive “Sustainability as a Growth Engine” Strategy

2024-10-1024:38

Returning to Growth with Hydrofarm CEO Bill Toler

2024-10-0931:15

Benzinga Cannabis Capital Conference Preview with Elliot Lane and Jesse Redmond

2024-10-0237:10

Shift4 Payments Initiating Coverage of Emerging Leader in Next-Gen Payment Technology Episode

2024-09-3011:47

Vivos Therapeutics Chairman and CEO Kirk Huntsman Discusses Recent FDA Clearance in Pediatric OSA

2024-09-2533:17

CEO Patrick Gruber on Synergies from the Red Trail Acquisition and How the Assets Complement Gevo’s Strategy

2024-09-2429:47

1-800-FLOWERS.COM Initiation of Coverage Review: Building a Pre-Eminent E-Commerce Gifting Platform

2024-09-2009:17

Gevo Initiation of Coverage Review: Delivering Carbon Abatement with Renewable Fuels and Technologies as Cost Effectively as Possible

2024-09-1921:01

Unusual Machines (UMAC) CEO Dr. Allan Evans Highlights Regulatory Changes Driving US Drone Market

2024-09-1823:47

The Future of Industrial IoT: AI, Network Resilience, and Data Center Evolution with Opengear's Patrick Quirk

2024-08-2828:01

On the Frontlines of Cybersecurity with Digital Executive Protection at BlackCloak

2024-08-1417:14

Water Tower Research unveils rebranded podcast series, now called WTR Small-Cap Spotlight

2024-08-0713:20

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

2024-07-3120:45

Ainos Inc. Director of Corporate Development Jack Lu on AI Nose Platform

2024-07-2418:04

Gorilla Technology IOC Discussion with WTR's President Shawn Severson and Technology Analyst Dr. John Roy

2024-07-1909:53

00:00

1.0x

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

#box-pro-ellipsis-173150698981254{-webkit-line-clamp:2;}CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need

Water Tower Research

CEO Doug Drysdale on Cybin's Novel Approach to Treat Psychiatric Disorders with High Unmet Need